High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens.
about
Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literatureHPLC-MS-MS Determination of ZCZ-011, A Novel Pharmacological Tool for Investigation of the Cannabinoid Receptor in Mouse Brain Using Clean Screen FASt™ Column Extraction.Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe.Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper.Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical IntoxicationFatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014.A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State.The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs.Recommendations for specimen collection for NBOMe analysis in clinical toxicology.Detection of 25C-NBOMe in Three Related Cases.Illicit Drug Analysis Using Two-Dimension Liquid Chromatography/Tandem Mass Spectrometry.LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening pow
P2860
Q26865329-EC798BAB-5FF5-41D8-B68A-7245D893DE55Q34465562-646C3BC6-8DF8-460D-AE07-36BE7B5C5961Q35749149-D8A0C9EB-E828-4ADD-9867-7C6ABBB6F23FQ36062676-8BD31B66-89D0-41AB-B683-7A1573E1211AQ36062680-9F3C6A44-5FCA-456C-AD53-D0BF8EFAF832Q38588257-6A1DB9D4-FEE1-4B74-9187-921EE90DB7B3Q38588258-3685F733-1223-4CEF-B0F3-DEDC2EED0797Q38669049-17DECA34-E09A-4254-BAB3-16045FBA1EEFQ39093171-4481CA7F-3768-4C61-828D-9D628229E39BQ40275494-F6938975-8B03-43E3-AD63-3260FC7E8F70Q42379355-12B89EF9-73C9-496C-8220-58B7D93EFA7AQ48721685-3B0CAA98-6CC9-4F3B-9077-67C8D8E97AC4Q51837730-4A78A541-4309-4A9C-A318-372C8836ED4DQ52760538-BE3716C3-72A1-42A3-BD7B-7CE9D1B0C944
P2860
High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-performance liquid chroma ...... gner drugs in urine specimens.
@en
High-performance liquid chroma ...... gner drugs in urine specimens.
@nl
type
label
High-performance liquid chroma ...... gner drugs in urine specimens.
@en
High-performance liquid chroma ...... gner drugs in urine specimens.
@nl
prefLabel
High-performance liquid chroma ...... gner drugs in urine specimens.
@en
High-performance liquid chroma ...... gner drugs in urine specimens.
@nl
P2093
P2860
P356
P1476
High-performance liquid chroma ...... gner drugs in urine specimens.
@en
P2093
Alphonse Poklis
Deborah J Clay
Justin L Poklis
P2860
P304
P356
10.1093/JAT/BKU005
P577
2014-02-16T00:00:00Z